APA aipamena

Yoshikawa, D., Ojima, H., Kokubu, A., Ochiya, T., Kasai, S., Hirohashi, S., & Shibata, T. (2009). Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Nature Publishing Group.

Chicago Style aipamena

Yoshikawa, D., H. Ojima, A. Kokubu, T. Ochiya, S. Kasai, S. Hirohashi, and T. Shibata. Vandetanib (ZD6474), an Inhibitor of VEGFR and EGFR Signalling, As a Novel Molecular-targeted Therapy against Cholangiocarcinoma. Nature Publishing Group, 2009.

MLA aipamena

Yoshikawa, D., et al. Vandetanib (ZD6474), an Inhibitor of VEGFR and EGFR Signalling, As a Novel Molecular-targeted Therapy against Cholangiocarcinoma. Nature Publishing Group, 2009.